American Journal of Cardiology
Volume 102, Issue 10 , Pages 1394-1398 , 15 November 2008

Association Between Renal Function and Circulating Levels of Natriuretic Peptides (from the Dallas Heart Study)

Received 8 July 2008 ,Accepted 13 July 2008.

References 

  1. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-Type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46:610–620
  2. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, et al Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001;76:1111–1119
  3. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR. Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem. 2007;53:1928–1935
  4. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91–97
  5. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93:1473–1480
  6. Katz J, Milliken MC, Stray-Gundersen J, Buja LM, Parkey RW, Mitchell JH, et al. Estimation of human myocardial mass with MR imaging. Radiology. 1988;169:495–498
  7. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension. 2005;46:124–129
  8. Salamone LM, Fuerst T, Visser M, Kern M, Lang T, Dockrell M, et al. Measurement of fat mass using DEXA: a validation study in elderly adults. J Appl Physiol. 2000;89:345–352
  9. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112:2163–2168
  10. Jain T, Peshock R, McGuire DK, Willett D, Yu Z, Vega GL, et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol. 2004;44:1011–1017
  11. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021
  12. Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem. 2004;41(Pt 6):459–463
  13. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 2001;10:785–792
  14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  15. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–937
  16. de Lemos JA, McGuire DK, Drazner MH. B-Type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322
  17. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(Pt 1):83–88
  18. Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Protter A, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996;271(Pt 2):R373–R380
  19. Ng LL, Geeranavar S, Jennings SC, Loke I, O'Brien RJ. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond). 2004;106:129–133
  20. Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Richards AM. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci (Lond). 1998;95:547–555
  21. Goetze JP, Jensen G, Moller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest. 2006;36:8–15
  22. Alehagen U, Lindstedt G, Eriksson H, Dahlstrom U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem. 2003;49:1337–1346
  23. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–353
  24. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007;9:787–794
  25. Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol. 2006;126:506–512
  26. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al B-Type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2004;41:571–579
  27. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis. 2004;44:420–428
  28. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005;46:118–123
  29. van Kimmenade RR, Januzzi JL, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, et al Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?. J Am Coll Cardiol. 2006;48:1621–1627

 The Dallas Heart Study was supported by the Donald W. Reynolds Foundation, United States Public Health Service General Clinical Research Center Grant M01-RR00633 from the National Institutes of Health/National Center for Research Resources-Clinical Research, with support and reagents from Roche Diagnostics, Indianapolis, Indiana, and Biosite Inc., San Diego, California. Dr. de Lemos has received consulting income from Biosite, Roche Diagnostics, and Inverness Medical, Innovations, Inc., Waltham, Massachussets; Dr. McGuire has received consulting income from Biosite; and Dr. Drazner has received consulting income from Inverness Medical.

PII: S0002-9149(08)01233-2

doi: 10.1016/j.amjcard.2008.07.018

American Journal of Cardiology
Volume 102, Issue 10 , Pages 1394-1398 , 15 November 2008

Article Tools

* Image Usage & Resolution